MAVENIR
27.2.2024 10:50:33 CET | Business Wire | Press release
solutions by stc, the leading enabler of digital transformation in Saudi Arabia and the region, announces an Open RAN agreement with Mavenir, the cloud-native network infrastructure provider building the future of networks, to launch the first commercial Open RAN network in Saudi Arabia. The announcement is a boost to stc’s Group strategic mission to deliver emerging technology to the Kingdom’s mobile customers, supporting the Vision 2030 digital transformation strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226664170/en/
Signing ceremony at Mobile World Congress (MWC) on stc stand in Hall 3. Executive company representatives: Yousef Almarshad, Chief Commercial Officer at solutions by stc & Pardeep Kohli, Chief Executive Office at Mavenir. (Photo: Business Wire)
The service is expected to go-live commercially with its next-generation Open RAN network in 2024, this decision follows a successful initial deployment for multi-layer 4G and 5G NSA Access Network on the Open RAN platform to stc, delivered in partnership with solutions by stc and Mavenir.
The newly launched multi-layered 4G and 5G Radio network will utilize Mavenir’s 4G Remote Radio Unit (RRU) and 5G Massive MIMO (mMIMO) Active Antenna Unit (AAU) technology and leverage the cloud-native Mavenir Webscale Platform (MWP) with fully containerized Centralized Unit (CU) and Distributed Unit (DU) software. The solution will run on x86 commercial-off-the-shelf (COTS) hardware platform that represents best-in-class technology for open interface radio systems. Mavenir and Saudi Arabia-based partner solutions by stc will provide stc with a cloud-native deployment solution that harnesses a full combination of expert professional services plus cutting-edge hardware and software and seamlessly integrated into stc’s radio network.
Yousef Almarshad, Chief Commercial Officer of solutions by stc commented: “Mavenir’s Open RAN technology innovation, together with solutions by stc unrivalled experience in the Saudia Arabia market, provide a strong foundation for this trail-blazing Open RAN deployment, bringing the next-generation performance and breakthrough services to stc’s valued customers across the Kingdom – going beyond data speeds to a more sustainably, securely and cost-effective network powered by Mavenir’s Open RAN.”
BG Kumar, President, Access Networks, Platforms and Digital Enablement at Mavenir, added: “Mavenir is extremely pleased to be awarded with the opportunity to build the first commercial Open RAN deployment in Saudi Arabia in collaboration with solutions by stc. Mavenir is confident that stc’s Open RAN network in Saudi Arabia will act as a catalyst for further accelerating operators’ digital transformation journeys across the Middle East region, ushering in a wave of customer-focused innovation that can fully leverage the unique potential generated by open standards and architecture.”
About stc Group:
stc group is an engine of digital transformation in the region, offering advanced solutions and driving the digitisation process. The group offers landline and fixed infrastructure, mobile and data services, and broadband & cloud computing services. www.stc.com.sa
About solutions by stc:
solutions by stc represents the driving force of digital transformation in the Kingdom of Saudi Arabia and the region, and the number one provider of information technology solutions in Saudi.
solutions aims to empower the public and private sectors by meeting the requirements of the digital age and adopting its latest trends. It also works to provide its customers with a diverse portfolio of services and products to support their daily operations, as the basic communications and information technology services provided by the company are designed to enable management and expansion of business.
solutions by stc started its operations more than 25 years ago and has provided its services to nearly 24,000 clients in 35 cities in Saudi Arabia and the region. The company's experience spans across several key sectors, including banking, healthcare, education, oil and gas, real estate, and telecom. The company has approximately 1,700 employees, including more than 1,000 with certifications in core technology areas. www.solutions.com.sa
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226664170/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom